Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073212 | 0.90 | CYP1A2 (0.49) | TP53HTTHDAC1 | |
| SCHEMBL10074089 | 0.88 | CYP1A2 (0.46) | TP53HTTHDAC1 | |
| SCHEMBL10074092 | 0.83 | MEN1 (0.58) | TP53MAPTHDAC1 | |
| SCHEMBL13534535 | 0.83 | HRH3 (0.51) | HTTHDAC1 | |
| SCHEMBL13534595 | 0.80 | MEN1 (0.57) | HDAC1 | |
| SCHEMBL573427 | 0.78 | HTT (0.60) | HTTMAPT | |
| SCHEMBL30454657 | 0.74 | PTGDR2 (0.44) | MAPTHDAC1 | |
| SCHEMBL22391864 | 0.74 | PTGDR2 (0.44) | MAPTHDAC1 | |
| SCHEMBL26501914 | 0.74 | MEN1 (0.52) | HTTHDAC1 | |
| SCHEMBL2709262 | 0.73 | HTT (0.53) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071590-B2 | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL SA (FR) | 2011-12-06 | — | — | US | disclosed |
| US-8071590-B2 | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL SA (FR) | 2011-12-06 | — | — | US | disclosed |
| EP-2145891-A1 | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL S.A. (FR) | 2010-01-20 | — | — | EP | disclosed |
| US-20100009980-A1 | NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2010-01-14 | — | — | US | disclosed |
| US-20100009980-A1 | NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009980-A1 | NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | Q6ZSR9, NQO2, RECQL | TP53 3381/4885HTT 4393/4885MAPT 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.